Identification of broadly neutralizing antibody epitopes in the HIV-1 envelope glycoprotein using evolutionary models

Virology Journal

Volumn 10, Issue , 2013, Pages

  Lacerda, Miguel ^a,b   Moore, Penny L ^c,d   Ngandu, Nobubelo K ^e   Seaman, Michael ^f   Gray, Elin S ^c   Murrell, Ben ^g,h   Krishnamoorthy, Mohan ⁱ   Nonyane, Molati ^c   Madiga, Maphuti ^c   Wibmer, Constantinos Kurt ^c   Sheward, Daniel ^e   Bailer, Robert T ^j   Gao, Hongmei ^k   Greene, Kelli M ^k   Karim, Salim S Abdool ^l,m   Mascola, John R ^j   Korber, Bette Tm ^i,n   Montefiori, David C ^k   Morris, Lynn ^c,d   Williamson, Carolyn ^e   Seoighe, Cathal ^a   more..

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

^d UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^e Department of Biomedical Sciences   (South Africa)

^f BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^g SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

^h STELLENBOSCH UNIVERSITY   (South Africa)

ⁱ LOS ALAMOS NATIONAL LABORATORY   (United States)

^j NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^k DUKE UNIVERSITY MEDICAL CENTER   (United States)

^l UNIVERSITY OF KWAZULU NATAL   (South Africa)

^m Och Spine at New York Presbyterian Hospitals   (United States)

ⁿ SANTA FE INSTITUTE   (United States)

more..

Author keywords

Antibodies; Epitope prediction; Evolutionary model; HIV; Neutralization sensitivity

Indexed keywords

AMINO ACID; EPITOPE; GLYCOPROTEIN GP 41; NEUTRALIZING ANTIBODY;

ALGORITHM; AMINO ACID ANALYSIS; AMINO ACID SEQUENCE; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ANTIGEN DETECTION; ARTICLE; BLOOD SAMPLING; CLADISTICS; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MOLECULAR EVOLUTION; NONHUMAN; PHYLOGENY; PROTEIN TERTIARY STRUCTURE; SEQUENCE ALIGNMENT; SITE DIRECTED MUTAGENESIS; VIRUS ENVELOPE; VIRUS NEUTRALIZATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ANTIBODIES, NEUTRALIZING; COMPUTATIONAL BIOLOGY; CROSS REACTIONS; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; EPITOPES; HIV ANTIBODIES; HIV-1;

EID: 84888593605     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-10-347     Document Type: Article

References (57)

1. Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. Tomaras GD, Yates NL, Liu P, Qin L, Fouda GG, Chavez LL, Decamp AC, Parks RJ, Ashley VC, Lucas JT, Cohen M, Eron J, Hicks CB, Liao H-X, Self SG, Landucci G, Forthal DN, Weinhold KJ, Keele BF, Hahn BH, Greenberg ML, Morris L, Karim SSA, Blattner WA, Montefiori DC, Shaw GM, Perelson AS, Haynes BF, J Virol 2008 82 12449 12463 10.1128/JVI.01708-08 18842730
2. HIV-1-specific antibody responses during acute and chronic HIV-1 infection. Tomaras GD, Haynes BF, Curr Opin HIV AIDS 2009 4 373 379 10.1097/COH.0b013e32832f00c0 20048700
3. The immune response during acute HIV-1 infection: clues for vaccine development. McMichael AJ, Borrow P, Tomaras GD, Goonetilleke N, Haynes BF, Nat Rev Immunol 2010 10 11 23 10.1038/nri2674 20010788
4. Antibody neutralization and escape by HIV-1. Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, Salazar-Gonzalez JF, Salazar MG, Kilby JM, Saag MS, Komarova NL, Nowak MA, Hahn BH, Kwong PD, Shaw GM, Nature 2003 422 307 312 10.1038/nature01470 12646921 (Pubitemid 36378357)
5. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Richman DD, Wrin T, Little SJ, Petropoulos CJ, Proc Natl Acad Sci USA 2003 100 4144 4149 10.1073/pnas.0630530100 12644702 (Pubitemid 36418171)
6. Evidence for potent autologous neutralizing antibody titers and compact envelopes in early infection with subtype C human immunodeficiency virus type 1. Li B, Decker JM, Johnson RW, Bibollet-Ruche F, Wei X, Mulenga J, Allen S, Hunter E, Hahn BH, Shaw GM, Blackwell JL, Derdeyn CA, J Virol 2006 80 5211 5218 10.1128/JVI.00201-06 16699001
7. Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection. Gray ES, Moore PL, Choge IA, Decker JM, Bibollet-Ruche F, Li H, Leseka N, Treurnicht F, Mlisana K, Shaw GM, Karim SSA, Williamson C, Morris L, J Virol 2007 81 6187 6196 10.1128/JVI.00239-07 17409164 (Pubitemid 46878025)
8. Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection. Frost SDW, Wrin T, Smith DM, Kosakovsky Pond SL, Liu Y, Paxinos E, Chappey C, Galovich J, Beauchaine J, Petropoulos CJ, Little SJ, Richman DD, Proc Natl Acad Sci USA 2005 102 18514 18519 10.1073/pnas.0504658102 16339909 (Pubitemid 43011257)
9. Escape from autologous neutralizing antibodies in acute/early subtype C HIV-1 infection requires multiple pathways. Rong R, Li B, Lynch RM, Haaland RE, Murphy MK, Mulenga J, Allen SA, Pinter A, Shaw GM, Hunter E, Robinson JE, Gnanakaran S, Derdeyn CA, PLoS Pathog 2009 5 1000594 10.1371/journal.ppat. 1000594 19763269
10. Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies. Doria-Rose NA, Klein RM, Manion MM, O'Dell S, Phogat A, Chakrabarti B, Hallahan CW, Migueles SA, Wrammert J, Ahmed R, Nason M, Wyatt RT, Mascola JR, Connors M, J Virol 2009 83 188 199 10.1128/JVI.01583-08 18922865
11. Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. Sather DN, Armann J, Ching LK, Mavrantoni A, Sellhorn G, Caldwell Z, Yu X, Wood B, Self S, Kalams S, Stamatatos L, J Virol 2009 83 757 769 10.1128/JVI.02036-08 18987148
12. The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection. Gray ES, Madiga MC, Hermanus T, Moore PL, Wibmer CK, Tumba NL, Werner L, Mlisana K, Sibeko S, Williamson C, Abdool Karim SS, Morris L, J Virol 2011 85 4828 4840 10.1128/JVI.00198-11 21389135
13. Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? Stamatatos L, Morris L, Burton DR, Mascola JR, Nat Med 2009 15 866 870 19525964
14. Cross-reactive neutralizing humoral immunity does not protect from HIV type 1 disease progression. Euler Z, van Gils MJ, Bunnik EM, Phung P, Schweighardt B, Wrin T, Schuitemaker H, J Infect Dis 2010 201 1045 1053 10.1086/651144 20170371
15. Genetic signatures in the envelope glycoproteins of HIV-1 that associate with broadly neutralizing antibodies. Gnanakaran S, Daniels MG, Bhattacharya T, Lapedes AS, Sethi A, Li M, Tang H, Greene K, Gao H, Haynes BF, Cohen MS, Shaw GM, Seaman MS, Kumar A, Gao F, Montefiori DC, Korber B, PLoS Comput Biol 2010 6 1000955 10.1371/journal.pcbi.1000955 20949103
16. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Kwong PD, Doyle ML, Casper DJ, Cicala C, Leavitt SA, Majeed S, Steenbeke TD, Venturi M, Chaiken I, Fung M, Katinger H, Parren PWIH, Robinson J, Van Ryk D, Wang L, Burton DR, Freire E, Wyatt R, Sodroski J, Hendrickson WA, Arthos J, Nature 2002 420 678 682 10.1038/nature01188 12478295 (Pubitemid 36764500)
17. Continuous viral escape and selection by autologous neutralizing antibodies in drug-naive human immunodeficiency virus controllers. Mahalanabis M, Jayaraman P, Miura T, Pereyra F, Chester EM, Richardson B, Walker B, Haigwood NL, J Virol 2009 83 662 672 10.1128/JVI.01328-08 18987151
18. Neutralizing antibody responses against autologous and heterologous viruses in acute versus chronic human immunodeficiency virus (HIV) infection: evidence for a constraint on the ability of HIV to completely evade neutralizing antibody responses. Deeks SG, Schweighardt B, Wrin T, Galovich J, Hoh R, Sinclair E, Hunt P, McCune JM, Martin JN, Petropoulos CJ, Hecht FM, J Virol 2006 80 6155 6164 10.1128/JVI.00093-06 16731954 (Pubitemid 43849193)
19. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Walker LM, Phogat SK, Chan-Hui P-Y, Wagner D, Phung P, Goss JL, Wrin T, Simek MD, Fling S, Mitcham JL, Lehrman JK, Priddy FH, Olsen OA, Frey SM, Hammond PW, Kaminsky S, Zamb T, Moyle M, Koff WC, Poignard P, Burton DR, Science 2009 326 285 289 10.1126/science.1178746 19729618
20. Broad neutralization coverage of HIV by multiple highly potent antibodies. Walker LM, Huber M, Doores KJ, Falkowska E, Pejchal R, Julien J-P, Wang S-K, Ramos A, Chan-Hui P-Y, Moyle M, Mitcham JL, Hammond PW, Olsen OA, Phung P, Fling S, Wong C-H, Phogat S, Wrin T, Simek MD, Principal Investigators PG, Koff WC, Wilson IA, Burton DR, Poignard P, Nature 2011 477 466 470 10.1038/nature10373 21849977
21. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Wu X, Yang Z-Y, Li Y, Hogerkorp C-M, Schief WR, Seaman MS, Zhou T, Schmidt SD, Wu L, Xu L, Longo NS, McKee K, O'Dell S, Louder MK, Wycuff DL, Feng Y, Nason M, Doria-Rose N, Connors M, Kwong PD, Roederer M, Wyatt RT, Nabel GJ, Mascola JR, Science 2010 329 856 861 10.1126/science.1187659 20616233
22. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Huang J, Ofek G, Laub L, Louder MK, Doria-Rose NA, Longo NS, Imamichi H, Bailer RT, Chakrabarti B, Sharma SK, Alam SM, Wang T, Yang Y, Zhang B, Migueles SA, Wyatt R, Haynes BF, Kwong PD, Mascola JR, Connors M, Nature 2012 491 406 412 10.1038/nature11544 23151583
23. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Burton DR, Pyati J, Koduri R, Sharp SJ, Thornton GB, Parren PW, Sawyer LS, Hendry RM, Dunlop N, Nara PL, Science 1994 266 1024 1027 10.1126/science.7973652 7973652 (Pubitemid 24373715)
24. A conformational switch in human immunodeficiency virus gp41 revealed by the structures of overlapping epitopes recognized by neutralizing antibodies. Pejchal R, Gach JS, Brunel FM, Cardoso RM, Stanfield RL, Dawson PE, Burton DR, Zwick MB, Wilson IA, J Virol 2009 83 8451 8462 10.1128/JVI.00685-09 19515770
25. The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. Sanders RW, Venturi M, Schiffner L, Kalyanaraman R, Katinger H, Lloyd KO, Kwong PD, Moore JP, J Virol 2002 76 7293 7305 10.1128/JVI.76.14.7293-7305.2002 12072528
26. The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of 1→2 mannose residues on the outer face of gp120. Scanlan CN, Pantophlet R, Wormald MR, Ollmann Saphire E, Stanfield R, Wilson IA, Katinger H, Dwek RA, Rudd PM, Burton DR, J Virol 2002 76 7306 7321 10.1128/JVI.76.14.7306-7321.2002 12072529
27. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. Zwick MB, Labrijn AF, Wang M, Spenlehauer C, Saphire EO, Binley JM, Moore JP, Stiegler G, Katinger H, Burton DR, Parren PWHI, J Virol 2001 75 10892 10905 10.1128/JVI.75.22.10892-10905.2001 11602729 (Pubitemid 33034579)
28. The role of antibodies in HIV vaccines. Mascola JR, Montefiori DC, Annu Rev Immunol 2010 28 413 444 10.1146/annurev-immunol-030409-101256 20192810
29. Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals. Tomaras GD, Binley JM, Gray ES, Crooks ET, Osawa K, Moore PL, Tumba N, Tong T, Shen X, Yates NL, Decker J, Wibmer CK, Gao F, Alam SM, Easterbrook P, Abdool Karim S, Kamanga G, Crump JA, Cohen M, Shaw GM, Mascola JR, Haynes BF, Montefiori DC, Morris L, J Virol 2011 85 11502 11519 10.1128/JVI.05363-11 21849452
30. Recent advances in B-cell epitope prediction methods. EL-Manzalawy Y, Honavar V, Immunome Research 2010 6 2
31. Towards a consensus on datasets and evaluation metrics for developing B-cell epitope prediction tools. Greenbaum JA, Andersen PH, Blythe M, Bui H-H, Cachau RE, Crowe J, Davies M, Kolaskar AS, Lund O, Morrison S, Mumey B, Ofran Y, Pellequer J-L, Pinilla C, Ponomarenko JV, Raghava GPS, van Regenmortel MHV, Roggen EL, Sette A, Schlessinger A, Sollner J, Zand M, Peters B, J Mol Recognit 2007 20 75 82 10.1002/jmr.815 17205610 (Pubitemid 46761248)
32. PEPITO: improved discontinuous B-cell epitope prediction using multiple distance thresholds and half sphere exposure. Sweredoski MJ, Baldi P, Bioinformatics 2008 24 1459 60 10.1093/bioinformatics/btn199 18443018 (Pubitemid 351851001)
33. Delineating antibody recognition in polyclonal sera from patterns of HIV-1 isolate neutralization. Georgiev IS, Doria-Rose NA, Zhou T, Kwon YD, Staupe RP, Moquin S, Chuang G-Y, Louder MK, Schmidt SD, Altae-Tran HR, Bailer RT, McKee K, Nason M, O'Dell S, Ofek G, Pancera M, Srivatsan S, Shapiro L, Connors M, Migueles SA, Morris L, Nishimura Y, Martin MA, Mascola JR, Kwong PD, Science 2013 340 751 756 10.1126/science.1233989 23661761
34. Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loop. Moore PL, Gray ES, Sheward D, Madiga M, Ranchobe N, Lai Z, Honnen WJ, Nonyane M, Tumba N, Hermanus T, Sibeko S, Mlisana K, Abdool Karim SS, Williamson C, Pinter A, Morris L, J Virol 2011 85 3128 3141 10.1128/JVI.02658-10 21270156
35. Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape. Moore PL, Gray ES, Wibmer CK, Bhiman JN, Nonyane M, Sheward DJ, Hermanus T, Bajimaya S, Tumba NL, Abrahams M-R, Lambson BE, Ranchobe N, Ping L, Ngandu N, Abdool Karim Q, Abdool Karim SS, Swanstrom RI, Seaman MS, Williamson C, Morris L, Nat Med 2012 18 1688 1692 10.1038/nm.2985 23086475
36. Enhancing exposure of HIV-1 neutralization epitopes through mutations in gp41. Blish CA, Nguyen M-A, Overbaugh J, PLoS Med 2008 5 9 10.1371/journal.pmed. 0050009 18177204 (Pubitemid 351198264)
37. The role of amino acid changes in the human immunodeficiency virus type 1 transmembrane domain in antibody binding and neutralization. Lovelace E, Xu H, Blish CA, Strong R, Overbaugh J, Virology 2011 421 235 244 10.1016/j.virol.2011. 09.032 22029936
38. An evolutionary-network model reveals stratified interactions in the V3 loop of the HIV-1 envelope. Poon AFY, Lewis FI, Pond SLK, Frost SDW, PLoS Comput Biol 2007 3 231 10.1371/journal.pcbi.0030231 18039027 (Pubitemid 350241951)
39. Broad neutralization of human immunodeficiency virus type 1 mediated by plasma antibodies against the gp41 membrane proximal external region. Gray ES, Madiga MC, Moore PL, Mlisana K, Abdool Karim SS, Binley JM, Shaw GM, Mascola JR, Morris L, J Virol 2009 83 11265 11274 10.1128/JVI.01359-09 19692477
40. Epitopes immediately below the base of the V3 loop of gp120 as targets for the initial autologous neutralizing antibody response in Two HIV-1 subtype B-infected individuals. Tang H, Robinson JE, Gnanakaran S, Li M, Rosenberg ES, Perez LG, Haynes BF, Liao H-X, LaBranche CC, Korber BT, Montefiori DC, J Virol 2011 85 9286 9299 10.1128/JVI.02286-10 21734041
41. Isolation of a human anti-HIV gp41 membrane proximal region neutralizing antibody by antigen-specific single B cell sorting. Morris L, Chen X, Alam M, Tomaras G, Zhang R, Marshall DJ, Chen B, Parks R, Foulger A, Jaeger F, Donathan M, Bilska M, Gray ES, Abdool Karim SS, Kepler TB, Whitesides J, Montefiori D, Moody MA, Liao H-X, Haynes BF, PLoS One 2011 6 23532 10.1371/journal.pone. 0023532 21980336
42. Epitope discovery with phylogenetic hidden Markov models. Lacerda M, Scheffler K, Seoighe C, Mol Biol Evol 2010 27 1212 1220 10.1093/molbev/msq008 20089717
43. Founder effects in the assessment of HIV polymorphisms and HLA allele associations. Bhattacharya T, Daniels M, Heckerman D, Foley B, Frahm N, Kadie C, Carlson J, Yusim K, McMahon B, Gaschen B, Mallal S, Mullins JI, Nickle DC, Herbeck J, Rousseau C, Learn GH, Miura T, Brander C, Walker B, Korber B, Science 2007 315 1583 6 10.1126/science.1131528 17363674 (Pubitemid 46449476)
44. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. McLellan JS, Pancera M, Carrico C, Gorman J, Julien J-P, Khayat R, Louder R, Pejchal R, Sastry M, Dai K, O'Dell S, Patel N, Shahzad-ul-Hussan S, Yang Y, Zhang B, Zhou T, Zhu J, Boyington JC, Chuang G-Y, Diwanji D, Georgiev I, Do Kwon Y, Lee D, Louder MK, Moquin S, Schmidt SD, Yang Z-Y, Bonsignori M, Crump JA, Kapiga SH, et al. Nature 2011 480 336 343 10.1038/nature10696 22113616
45. Phylogenies and the comparative method. Felsenstein J, Am Nat 1985 125 1 15 10.1086/284325 (Pubitemid 16276188)
46. Phylogenetic comparative analysis: a modeling approach for adaptive evolution. Butler MA, King AA, Am Nat 2004 164 683 695 10.1086/426002 (Pubitemid 40099523)
47. Phylogenetic analysis using lévy processes: finding jumps in the evolution of continuous traits. Landis MJ, Schraiber JG, Liang M, Syst Biol 2013 62 193 204 10.1093/sysbio/sys086 23034385
48. Establishing a cohort at high risk of HIV infection in South Africa: challenges and experiences of the CAPRISA 002 acute infection study. Van Loggerenberg F, Mlisana K, Williamson C, Auld SC, Morris L, Gray CM, Abdool Karim Q, Grobler A, Barnabas N, Iriogbe I, Abdool Karim SS, PLoS One 2008 3 1954 10.1371/journal.pone.0001954 18414658 (Pubitemid 352003412)
49. GARD: a genetic algorithm for recombination detection. Kosakovsky Pond SL, Posada D, Gravenor MB, Woelk CH, Frost SDW, Bioinformatics 2006 22 3096 3098 10.1093/bioinformatics/btl474 17110367 (Pubitemid 44884087)
50. Coalescent simulation of intracodon recombination. Arenas M, Posada D, Genetics 2010 184 429 437 10.1534/genetics.109.109736 19933876
51. A simple, fast, and accurate algorithm to estimate large phylogenies by maximum likelihood. Guindon S, Gascuel O, Syst Biol 2003 52 696 704 10.1080/10635150390235520 14530136 (Pubitemid 37365050)
52. Evolutionary distances for protein-coding sequences: modeling site-specific residue frequencies. Halpern AL, Bruno WJ, Mol Biol Evol 1998 15 910 7 10.1093/oxfordjournals.molbev.a025995 9656490 (Pubitemid 28321889)
53. Modeling HIV-1 drug resistance as episodic directional selection. Murrell B, de Oliveira T, Seebregts C, Kosakovsky Pond SL, Scheffler K, on behalf of the Southern African Treatment and Resistance Network (SATuRN) Consortium, PLoS Comput Biol 2012 8 1002507 10.1371/journal.pcbi.1002507 22589711
54. HyPhy: hypothesis testing using phylogenies. Kosakovsky Pond SL, Frost SDW, Muse SV, Bioinformatics 2005 21 676 9 10.1093/bioinformatics/bti079 15509596 (Pubitemid 40424796)
55. Bayes factors. Kass RE, Raftery AE, J Am Stat Assoc 1995 90 773 795 10.1080/01621459.1995.10476572
56. Size, power and false discovery rates. Efron B, Ann Statist 2007 35 1351 1377 10.1214/009053606000001460
57. Introducing Markov chain Monte Carlo. Gilks WR, Richardson S, Spiegelhalter DJ, Markov Chain Monte Carlo in Practice United States of America: Chapman and Hall/CRC, Gilks WR, Richardson S, Spiegelhalter DJ, 1996 1 19